Dyadic International, Inc. (OTCQX: DYAI)  is a global biotechnology company focused on further improving and leveraging the patented and proprietary C1 expression system to help bring biologic vaccines and drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers to improve access and cost to patients and the healthcare system - but most importantly to save lives.

Biotechnology

Dyadic International

Mark A. Emalfarb

Joseph Hazelton

Joe Hazelton

Ping W. Rawson

The Business Development and Licensing team at Dyadic International is responsible for identifying and pursuing strategic partnerships and licensing opportunities that enhance the company's C1 expression system. They work collaboratively with research and development to align business goals with innovative biotech solutions, aiming to accelerate the development and commercialization of biologic vaccines and drugs. Their efforts are focused on optimizing market access, improving patient outcomes, and driving revenue growth for the company.

Business Development and Licensing

About

Team members

Other teams at Dyadic International

Leadership Team

Finance and Accounting